John F. Enders Lecture 2006: Antivirals for influenza

Journal of Infectious Diseases

Volumn 196, Issue 2, 2007, Pages 181-190

  Ong, Adrian K ^a,c   Hayden, Frederick G ^b,d  

^a Strat Devmt/Monit Erad/Eliminat   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 315675; A 32278; ADAMANTANE; ALPHA INTERFERON; AMANTADINE; ANTIBIOTIC AGENT; ANTIBODY; ANTIVIRUS AGENT; APROTININ; CS 8958; CYANOVIRIN N; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 6; OSELTAMIVIR; PERAMIVIR; PLACEBO; R 118958; RIBAMIDINE; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; SIALYLGLYCOPOLYMER; SMALL INTERFERING RNA; T 705; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; ZANAMIVIR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AVIAN INFLUENZA; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; META ANALYSIS; MONOTHERAPY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 34447258584     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518939     Document Type: Review

References (118)

1. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antivir Res 2006; 71:372-8.
2. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2001; 194(Suppl 2):S119-26.
3. Hayden FG. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J 2004; 23:S262-9.
4. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827-35.
5. Hirst GK. Adsorption of influenza hemagglutinins and virus by red blood cells. J Exp Med 1942; 76:195-209.
6. Burnet FM, McCrea JF, Stone JD. Modification of human red cells by virus action. 1. The receptor gradient for virus action in human red cells. Br J Exp Pathol 1946; 27: 228-36.
7. Burnet FM, Stone JD. The receptor-destroying enzyme of V-cholerae. Aust J Exp Biol Med Sci 1947; 25:227-33.
8. Anderson SG, Burnet FM, Fazekas de St. Groths BF, McCrea JF, Stone JD. Mucins and mucoids in relation to influenza virus action. VI. general discussion. Aust J Exp Biol Med Sci 1948; 26:403-11.
9. Bergelson LD, Bukrinskaya AG, Prokazova NV, et al. Role of gangliosides in reception of influenza virus. Eur J Biochem 1982; 128: 467-74.
10. Griffin JA, Basak S, Compans RW. Effects of hexose starvation and the role of sialic acid in influenza virus release. Virology 1983; 125: 324-34.
11. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-9.
12. Gottschalk A. The influenza virus enzyme and its mucoprotein substrate. Yale J Biol Med 1954; 26:352-64.
13. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976; 33:159-63.
14. Palese P, Schulman JL, Bodo G, Meindl P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N- trifluoroacetylneuraminic acid (FANA). Virology 1974; 59:490-8.
15. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983; 303:35-40.
16. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-23.
17. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3- dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37:1473-9.
18. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119:681-90.
19. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42:647-53.
20. Hayden FG, Aoki FY. Influenza neuraminidase inhibitors. In: Yu VL, ed. Antimicrobial therapy and vaccines. Vol. 2, 2nd ed. Pittsburgh: ESun Technologies, 2005:773-89.
21. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
22. Wilson SZ, Knight V, Wyde PR, Drake S, Couch RB. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980; 17:642-8.
23. Hayden FG, Hall WJ, Douglas RG Jr, Speers DM. Amantadine aerosols in normal volunteers: pharmacology and safety testing. Antimicrob Agents Chemother 1979; 16: 644-50.
24. Hayden F, Hall WJ, Douglas RG Jr. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis 1980; 141:535-42.
25. Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999; 4:143-9.
26. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-9.
27. Cass LMR Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36(Suppl 1):1-11.
28. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000; 30:587-9.
29. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 1986; 314:65-70.
30. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314:71-5.
31. Tannock GA, Gillett SM, Gillett RS, et al. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect 1988; 101:611-21.
32. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282-9.
33. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-8.
34. Gravenstein S, Drinks P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359-66.
35. Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969; 2:1026-8.
36. Bricaire F, Hannoun C, Boissel JP. Prevention of influenza A: effectiveness and tolerance of rimantadine hydrochloride [in French]. Presse Med 1990; 19:69-72.
37. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285:748-54.
38. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
39. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440-9.
40. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-80.
41. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
42. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-6.
43. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025-31.
44. Ferguson N, Cummings D, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437:209-14.
45. Longini IJ, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309:1083-7.
46. World Health Organization (WHO). WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza. Available at: http://www.who.int/csr/disease/ avian_influenza/guidelines/draftprotocol/en/ index.html. Accessed 29 May 2007.
47. Gubareva LV, Novikov DV, Hayden FG. Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in families. J Infect Dis 2002; 186:1575-81.
48. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007; 165:212-21.
49. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
50. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21: 761-8.
51. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
52. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.
53. Lee N, Chan P, Choi K, Hui D, Cockram C, Sung J. Factors associated with early hospital discharge of adult influenza patients [presentation V-2041a]. In: Late breaker abstract program of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006:190.
54. McGeer A, Siddiqi N, Green KA, Low DE. Outcomes of influenza requiring hospital admission in Ontario, Canada: two years of surveillance [presentation V-1696]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco): Washington, DC: American Society for Microbiology, 2006:455.
55. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J Clin Invest 1998; 101:643-9.
56. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180: 586-93.
57. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-20.
58. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-9.
59. Writing Committee of the World Health Organization Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-85.
60. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7.
61. World Health Organization (WHO). WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. Available at: http: //www.who.int/csr/disease/avian_influenza/ guidelines/pharmamanagement/en/index .html. Accessed 29 May 2007.
62. World Health Organization (WHO). Summary of the second WHO consultation on clinical aspects of human infection with avian influenza A(H5N1) virus. Available at: http://www.who.int/csr/disease/avian _influenza/meeting19_03_2007/ en/index .html. Accessed 29 May 2007.
63. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
64. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192: 665-72.
65. Govorkova E, Ilyushina N, Boltz D, Douglas A, Yilmaz N, Webster R. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51:1414-24.
66. Cochran KW, Maassab HF, Tsunoda A, Berlin BS. Studies on the antiviral activity of amantadine hydrochloride. Ann NY Acad Sci 1965; 130:432-9.
67. Hayden FG, Cote KM, Douglas RG Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980; 17:865-70.
68. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4.
69. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18(Suppl B): 19-29.
70. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001; 356:1895-7.
71. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
72. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193: 760-4.
73. Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. N Engl J Med 2006; 354: 785-8.
74. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275-82.
75. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-7.
76. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134:988-97.
77. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-24.
78. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352-5.
79. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl 1): i5-21.
80. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188: 57-61.
81. Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull World Health Organ 1969; 41:677-82.
82. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991; 164:969-72.
83. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 1989; 159:1050-6.
84. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-30.
85. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81.
86. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 249-57 (in this issue).
87. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-72.
88. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-31.
89. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
90. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
91. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Red 2007; 82:149-50.
92. Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 2003; 51:977-90.
93. Stilianakis N, Perelson A, Hayden F. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998; 177:863-73.
94. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001; 49:147-56.
95. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50: 2395-402.
96. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005; 80:156.
97. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuramidinase inhibitors. JAMA 2007; 297:1435-42.
98. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-20.
99. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-50.
100. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-9.
101. Lavrov SV, Eremkina EI, Orlova TG, Galegov GA, Soloviev VD, Zhdanov VM. Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature 1968; 217:856-7.
102. Hayden FG, Douglas RG Jr, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980; 18: 536-41.
103. Hayden FG, Schlepushkin AN, Pushkarskaya NL. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984; 25:53-7.
104. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother 1986; 18(Suppl B): 177-83.
105. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70:121-31.
106. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48: 101-15.
107. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-90.
108. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
109. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 2006; 80:11960-7.
110. Sidwell R, Barnard D, Day C, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-51.
111. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101:8676-81.
112. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7:126.
113. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice. Respir Res 2006; 7:43.
114. Bantia S, Arnold C, Parker C, Upshaw R, Chang P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39-45.
115. Ison M, Mishin V, Braciale T, Hayden F, Gubareva L. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006; 193: 765-72.
116. MacDonald SJF, Watson KG, Cameron R, et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once weekly dosing regimen. Antimicrob Agents Chemother 2004; 48:4542-9.
117. Southeast Asia Influenza Clinical Research Network. Available at: http://www .seaclinicalresearch.org. Accessed 29 May 2007.
118. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006; 12:73-7.